Evidence map›Paper›PMID 41003992›Full record

ArticleBulletin of experimental biology and medicine2025

Evaluation of Transferrin Level in Iron Supplementation after Partial Hepatectomy.

Weiwei Fang, Chang Pang, Xiying Li

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weiwei FangDepartment of Blood Transfusion, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chang PangDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Xiying LiDepartment of Blood Transfusion, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lixiying@cicams.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we studied the effect of partial hepatectomy in patients with liver cancer (n = 48) on the level of serum iron and whether it can be corrected with iron supplementation therapy (IST; daily for 9 days). To identify whether the rapid decline in serum iron occurs only after hepatectomy, we studied this parameter in patients after pneumonectomy (n = 41). The hematocrit (HCT) and hemoglobin (HGB) levels were assayed by complete and differential blood counts, serum transferrin (TRF) and serum iron levels were measured by immunoturbidimetry and TPTZ (2,4,6-tri-(2-pyridyl)-5-triazine) method, respectively. After partial hepatectomy, the levels of serum iron and TRF in peripheral blood significantly decreased in comparison with the levels before surgery (p < 0.001). No significant elevation of serum iron and TRF was observed immediately after termination of IST, although these levels increased significantly 30 days after the onset of the therapy. Similar changes were observed in the control group in the same time points after the surgery, so IST exerted no positive effect. In contrast, both the incidence of intensive care unit admission and iron overload were higher in the IST group in comparison with the control. Serum iron sharply decreased after partial hepatectomy, which could be mainly due to the decrease in TRF. IST after hepatectomy did not improve HGB level. Thus, IST after partial hepatectomy was ineffective.

Indexed as

Dietary SupplementsHepatectomyIronTransferrinAdultAgedBlood Loss, SurgicalFemaleHematocritHemoglobinsHumansIron OverloadLiver NeoplasmsMaleMiddle AgedPneumonectomyHemoglobinsIronTransferrinHepatic ischemia/reperfusion injuryHepatocellular carcinomaIron supplementationTransferrin

Identifiers

PMID41003992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.